Claire Crafter
Overview
Explore the profile of Claire Crafter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walker L, Duncan R, Adamson B, Kendall H, Brittain N, Luzzi S, et al.
Mol Cancer Res
. 2024 Sep;
22(12):1128-1142.
PMID: 39348093
Resistance to androgen receptor (AR)-targeted therapies represents a major challenge in prostate cancer. A key mechanism of treatment resistance in patients who progress to castration-resistant prostate cancer (CRPC) is the...
2.
Bagal S, Astles P, Diene C, Argyrou A, Crafter C, Cassar D, et al.
J Med Chem
. 2024 Jul;
67(14):11732-11750.
PMID: 38991141
Androgen receptor (AR) signaling plays a key role in the progression of prostate cancer. This study describes the discovery and optimization of a novel series of AR PROTAC degraders that...
3.
Hayhow T, Williamson B, Lawson M, Cureton N, Braybrooke E, Campbell A, et al.
Commun Biol
. 2024 May;
7(1):563.
PMID: 38740899
Targeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the development of a VHL-targeting and...
4.
Bashi A, Coker E, Bulusu K, Jaaks P, Crafter C, Lightfoot H, et al.
Cancer Discov
. 2024 Mar;
14(5):846-865.
PMID: 38456804
Significance: We present the largest cancer drug combination screen published to date with 7 × 7 concentration response matrices for 109 combinations in more than 750 cell lines, complemented by...
5.
Erickson E, You I, Perry G, Dugourd A, Donovan K, Crafter C, et al.
Sci Signal
. 2024 Feb;
17(825):eadf2670.
PMID: 38412255
More than 50% of human tumors display hyperactivation of the serine/threonine kinase AKT. Despite evidence of clinical efficacy, the therapeutic window of the current generation of AKT inhibitors could be...
6.
Clayton N, Fox M, Vicente-Garcia J, Schroeder C, Littlewood T, Wilde J, et al.
J Biol Chem
. 2022 Apr;
298(6):101916.
PMID: 35429500
Activated Cdc42-associated kinase (ACK) is an oncogenic nonreceptor tyrosine kinase associated with poor prognosis in several human cancers. ACK promotes proliferation, in part by contributing to the activation of Akt,...
7.
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase
Degorce S, Tavana O, Banks E, Crafter C, Gingipalli L, Kouvchinov D, et al.
J Med Chem
. 2020 Aug;
63(18):10460-10473.
PMID: 32803978
We report the first disclosure of IRAK3 degraders in the scientific literature. Taking advantage of an opportune byproduct obtained during our efforts to identify IRAK4 inhibitors, we identified ready-to-use, selective...
8.
Goncalves E, Segura-Cabrera A, Pacini C, Picco G, Behan F, Jaaks P, et al.
Mol Syst Biol
. 2020 Jul;
16(7):e9405.
PMID: 32627965
Low success rates during drug development are due, in part, to the difficulty of defining drug mechanism-of-action and molecular markers of therapeutic activity. Here, we integrated 199,219 drug sensitivity measurements...
9.
Fox M, Crafter C, Owen D
Biochem Soc Trans
. 2019 Dec;
47(6):1715-1731.
PMID: 31845724
Activated Cdc42-associated kinase or ACK, is a non-receptor tyrosine kinase and an effector protein for the small G protein Cdc42. A substantial body of evidence has accumulated in the past...
10.
Tovell H, Testa A, Zhou H, Shpiro N, Crafter C, Ciulli A, et al.
ACS Chem Biol
. 2019 Aug;
14(9):2024-2034.
PMID: 31461270
SGK3 is a PX domain containing protein kinase activated at endosomes downstream of class 1 and 3 PI3K family members by growth factors and oncogenic mutations. SGK3 plays a key...